1. Tuttle, K.R.; Bakris, G.L.; Bilous, R.W.; Chiang, J.L.; de Boer, I.H.; Goldstein-Fuchs, J.; Hirsch, I.B.; Kalantar-Zadeh, K.; Narva, A.S.; Navaneethan, S.D.; et al. Diabetic kidney disease: A report from an ADA Consensus Conference. Am. J. Kidney Dis. 2014, 64, 510–533. [CrossRef] [PubMed]
2. Neal, B.; Perkovic, V.; Mahaffey, K.W.; De Zeeuw, D.; Fulcher, G.; Erondu, N.; Shaw, W.; Law, G.; Desai, M.; Matthews, D.R. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N. Engl. J. Med. 2017, 377, 644–657. [CrossRef]
3. Zinman, B.; Wanner, C.; Lachin, J.M.; Fitchett, D.H.; Bluhmki, E.; Hantel, S.; Mattheus, M.; Devins, T.; Johansen, O.E.; Woerle, H.J.; et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N. Engl. J. Med. 2015, 373, 2117–2128. [CrossRef]
4. Wanner, C.; Inzucchi, S.E.; Lachin, J.M.; Fitchett, D.; Von Eynatten, M.; Mattheus, M.; Johansen, O.E.; Woerle, H.J.; Broedl, U.C.; Zinman, B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N. Engl. J. Med. 2016, 375, 323–334. [CrossRef]
5. Vallon, V.; Thomson, S.C. The tubular hypothesis of nephron filtration and diabetic kidney disease. Nat. Rev. Nephrol. 2020, 16, 317–336. [CrossRef]
6. Cherney, D.Z.; Perkins, B.A.; Soleymanlou, N.; Maione, M.; Lai, V.; Lee, A.; Fagan, N.M.; Woerle, H.J.; Johansen, O.E.; Broedl, U.C.; et al. Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients with Type 1 Diabetes Mellitus. Circulation 2014, 129, 587–597. [CrossRef]
7. Kamezaki, M.; Kusaba, T.; Komaki, K.; Fushimura, Y.; Watanabe, N.; Ikeda, K.; Kitani, T.; Yamashita, N.; Uehara, M.; Kirita, Y.; et al. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Sci. Rep. 2018, 8, 1–14. [CrossRef]
8. Hosokawa, K.; Takata, T.; Sugihara, T.; Matono, T.; Koda, M.; Kanda, T.; Taniguchi, S.; Ida, A.; Mae, Y.; Yamamoto, M.; et al. Ipragliflozin Ameliorates Endoplasmic Reticulum Stress and Apoptosis through Preventing Ectopic Lipid Deposition in Renal Tubules. Int. J. Mol. Sci. 2019, 21, 190. [CrossRef]
9. Montani, J.-P.; Carroll, J.F.; Dwyer, T.M.; Antic, V.; Yang, Z.; Dulloo, A. Ectopic fat storage in heart, blood vessels and kidneys in the pathogenesis of cardiovascular diseases. Int. J. Obes. 2004, 28, S58–S65. [CrossRef] [PubMed]
10. Hou, N.; Han, F.; Wang, M.; Huang, N.; Zhao, J.; Liu, X.; Sun, X. Perirenal fat associated with microalbuminuria in obese rats. Int. Urol. Nephrol. 2014, 46, 839–845. [CrossRef] [PubMed]
11. Geraci, G.; Zammuto, M.M.; Mattina, A.; Zanoli, L.; Geraci, C.; Granata, A.; Nardi, E.; Fatuzzo, P.M.; Cottone, S.; Mulè, G. Para-perirenal distribution of body fat is associated with reduced glomerular filtration rate regardless of other indices of adiposity in hypertensive patients. J. Clin. Hypertens. 2018, 20, 1438–1446. [CrossRef]
12. Dwyer, T.M.; Mizelle, H.L.; Cockrell, K.; Buhner, P. Renal sinus lipomatosis and body composition in hypertensive, obese rabbits. Int. J. Obes. Relat. Metab. Disord. J. Int. Assoc. Study Obes. 1995, 19, 869–874.
13. Liu, Y.; Wang, L.; Luo, M.; Chen, N.; Deng, X.; He, J.; Zhang, L.; Luo, P.; Wu, J. Inhibition of PAI-1 attenuates perirenal fat inflammation and the associated nephropathy in high-fat diet-induced obese mice. Am. J. Physiol. Metab. 2019, 316, E260–E267. [CrossRef] [PubMed]
14. Li, H.; Li, M.; Liu, P.; Wang, Y.; Zhang, H.; Li, H.; Yang, S.; Song, Y.; Yin, Y.; Gao, L.; et al. Telmisartan Ameliorates Nephropathy in Metabolic Syndrome by Reducing Leptin Release from Perirenal Adipose Tissue. Hypertension 2016, 68, 478–490. [CrossRef] [PubMed]
15. Miyachi, Y.; Tsuchiya, K.; Shiba, K.; Mori, K.; Komiya, C.; Ogasawara, N.; Ogawa, Y. A reduced M1-like/M2-like ratio of macrophages in healthy adipose tissue expansion during SGLT2 inhibition. Sci. Rep. 2018, 8, 1–13. [CrossRef]
16. Shiba, K.; Tsuchiya, K.; Komiya, C.; Miyachi, Y.; Mori, K.; Shimazu, N.; Yamaguchi, S.; Ogasawara, N.; Katoh, M.; Itoh, M.; et al. Canagliflozin, an SGLT2 inhibitor, attenuates the development of hepatocellular carcinoma in a mouse model of human NASH. Sci. Rep. 2018, 8, 2362. [CrossRef] [PubMed]
17. Komiya, C.; Tsuchiya, K.; Shiba, K.; Miyachi, Y.; Furuke, S.; Shimazu, N.; Yamaguchi, S.; Kanno, K.; Ogawa, Y. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction. PLoS ONE 2016, 11, e0151511. [CrossRef]
18. Mori, K.; Tsuchiya, K.; Nakamura, S.; Miyachi, Y.; Shiba, K.; Ogawa, Y.; Kitamura, K. Ipragliflozin-induced adipose expansion inhibits cuff-induced vascular remodeling in mice. Cardiovasc. Diabetol. 2019, 18, 1–12. [CrossRef] [PubMed]
19. Bell, C.W.; Jiang, W.; Reich, C.F.; Pisetsky, D.S. The extracellular release of HMGB1 during apoptotic cell death. Am. J. Physiol. Cell Physiol. 2006, 291, C1318–C1325. [CrossRef]
20. Johnson, R.J. What mediates progressive glomerulosclerosis? The glomerular endothelium comes of age. Am. J. Pathol. 1997, 151, 1179–1181.
21. Schwartz, M.W.; Woods, S.C.; Porte, D., Jr.; Seeley, R.J.; Baskin, D.G. Central nervous system control of food intake. Nature 2000, 404, 661–671. [CrossRef]
22. Gal, C.S.-L.; Raufaste, D.; Brossard, G.; Pouzet, B.; Marty, E.; Maffrand, J.-P.; Le Fur, G. Characterization and localization of leptin receptors in the rat kidney. FEBS Lett. 1997, 404, 185–191. [CrossRef]
23. Wolf, G.; Hamann, A.; Han, D.C.; Helmchen, U.; Thaiss, F.; Ziyadeh, F.N.; Stahl, R.A. Leptin stimulates proliferation and TGF-beta expression in renal glomerular endothelial cells: Potential role in glomerulosclerosis [seecomments]. Kidney Int. 1999, 56, 860–872. [CrossRef] [PubMed]
24. Chodavarapu, H.; Grobe, N.; Somineni, H.K.; Salem, E.S.B.; Madhu, M.; Elased, K.M. Rosiglitazone Treatment of Type 2 Diabetic db/db Mice Attenuates Urinary Albumin and Angiotensin Converting Enzyme 2 Excretion. PLoS ONE 2013, 8, e62833. [CrossRef] [PubMed]
25. Kawanami, D.; Takashi, Y.; Takahashi, H.; Motonaga, R.; Tanabe, M. Renoprotective Effects of DPP-4 Inhibitors. Antioxidants 2021, 10, 246. [CrossRef]
26. Wang, C.; Li, L.; Liu, S.; Liao, G.; Li, L.; Chen, Y.; Cheng, J.; Lu, Y.; Liu, J. GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis. PLoS ONE 2018, 13, e0193473. [CrossRef] [PubMed]
27. Shimizu, M.; Furuichi, K.; Toyama, T.; Kitajima, S.; Hara, A.; Kitagawa, K.; Iwata, Y.; Sakai, N.; Takamura, T.; Yoshimura, M.; et al. Long-Term Outcomes of Japanese Type 2 Diabetic Patients with Biopsy-Proven Diabetic Nephropathy. Diabetes Care 2013, 36, 3655–3662. [CrossRef]
28. Ballermann, B.J. A role for leptin in glomerulosclerosis? Kidney Int. 1999, 56, 1154–1155. [CrossRef]
29. Liu, B.X.; Sun, W.; Kong, X.Q. Perirenal Fat: A Unique Fat Pad and Potential Target for Cardiovascular Disease. Angiology 2019, 70, 584–593. [CrossRef]
30. Lau, W.B.; Ohashi, K.; Wang, Y.; Ogawa, H.; Murohara, T.; Ma, X.-L.; Ouchi, N. Role of Adipokines in Cardiovascular Disease. Circ. J. 2017, 81, 920–928. [CrossRef]
31. Ndisang, J.F.; Jadhav, A.; Mishra, M. The heme oxygenase system suppresses perirenal visceral adiposity, abates renal inflamma- tion and ameliorates diabetic nephropathy in Zucker diabetic fatty rats. PLoS ONE 2014, 9, e87936.
32. Morley, T.S.; Xia, J.Y.; Scherer, P.E. Selective enhancement of insulin sensitivity in the mature adipocyte is sufficient for systemic metabolic improvements. Nat. Commun. 2015, 6, 7906. [CrossRef]
33. Tanaka, M.; Ikeda, K.; Suganami, T.; Komiya, C.; Ochi, K.; Shirakawa, I.; Hamaguchi, M.; Nishimura, S.; Manabe, I.; Matsuda, T.; et al. Macrophage-inducible C-type lectin underlies obesity-induced adipose tissue fibrosis. Nat. Commun. 2014, 5, 4982. [CrossRef]
34. Okuno, Y.; Fukuhara, A.; Hashimoto, E.; Kobayashi, H.; Kobayashi, S.; Otsuki, M.; Shimomura, I. Oxidative Stress Inhibits Healthy Adipose Expansion Through Suppression of SREBF1-Mediated Lipogenic Pathway. Diabetes 2018, 67, 1113–1127. [CrossRef]
35. Shimazu, T.; Hirschey, M.D.; Newman, J.; He, W.; Shirakawa, K.; Le Moan, N.; Grueter, C.A.; Lim, H.; Saunders, L.R.; Stevens, R.D.; et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 2013, 339, 211–214. [CrossRef]
36. Sztalryd, C.; Brasaemle, D.L. The perilipin family of lipid droplet proteins: Gatekeepers of intracellular lipolysis. Biochim. Biophys. Acta BBA Mol. Cell Biol. Lipids 2017, 1862, 1221–1232. [CrossRef]
37. Brasaemle, D.L. Thematic review series: Adipocyte Biology. The perilipin family of structural lipid droplet proteins: Stabilization of lipid droplets and control of lipolysis. J. Lipid Res. 2007, 48, 2547–2559. [CrossRef] [PubMed]
38. Akira, S.; Takeda, K. Toll-like receptor signalling. Nat. Rev. Immunol. 2004, 4, 499–511. [CrossRef] [PubMed]
39. Devaraj, S.; Dasu, M.R.; Park, S.H.; Jialal, I.; Devaraj, S.; Dasu, M.R.; Park, S.H.; Jialal, I. Increased levels of ligands of Toll-like receptors 2 and 4 in type 1 diabetes. Diabetologia 2009, 52, 1665–1668. [CrossRef]
40. Wu, H.; Ma, J.; Wang, P.; Corpuz, T.M.; Panchapakesan, U.; Wyburn, K.R.; Chadban, S.J. HMGB1 Contributes to Kidney Ischemia Reperfusion Injury. J. Am. Soc. Nephrol. 2010, 21, 1878–1890. [CrossRef] [PubMed]
41. Ma, J.; Chadban, S.J.; Zhao, C.Y.; Chen, X.; Kwan, T.; Panchapakesan, U.; Pollock, C.A.; Wu, H. TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PLoS ONE 2014, 9, e97985. [CrossRef] [PubMed]
42. Ma, J.; Wu, H.; Zhao, C.Y.; Panchapakesan, U.; Pollock, C.; Chadban, S.J. Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. Int. J. Clin. Exp. Pathol. 2014, 7, 481–495.
43. Mudaliar, H.; Pollock, C.; Komala, M.G.; Chadban, S.; Wu, H.; Panchapakesan, U. The role of Toll-like receptor proteins (TLR) 2 and 4 in mediating inflammation in proximal tubules. Am. J. Physiol. Physiol. 2013, 305, F143–F154. [CrossRef] [PubMed]
44. Chen, X.; Ma, J.; Kwan, T.; Stribos, E.G.D.; Messchendorp, A.L.; Loh, Y.W.; Wang, X.; Paul, M.; Cunningham, E.C.; Habib, M.; et al. Blockade of HMGB1 Attenuates Diabetic Nephropathy in Mice. Sci. Rep. 2018, 8, 1–13. [CrossRef] [PubMed]